Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
U.S. Stock Futures Edge Higher as Micron Earnings Boost AI Sentiment Ahead of CPI Data 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
RBA Unlikely to Cut Interest Rates in 2026 as Inflation Pressures Persist, Says Westpac 
BoE Set to Cut Rates as UK Inflation Slows, but Further Easing Likely Limited 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Oil Prices Steady in Asia but Headed for Weekly Loss on Supply Glut Concerns 
Asian Stocks Slide as AI Spending Fears and Global Central Bank Decisions Weigh on Markets 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Oil Prices Rebound as Trump Orders Blockade of Sanctioned Venezuelan Tankers 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
